MYC and prostate carcinoma: The degradation of MYC partners by PROTACs has proven successful in clinical models for ARV-771, which depletes the expression of MYC by degrading of BET proteins even in castration-resistant prostate cancer and MZ1, which exhibited anticancer effects in acute myeloid leukemia by targeting MYC [28, 29].